Search results for "follicular thyroid cancer"

showing 5 items of 5 documents

Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours

2017

Distinguishing between follicular thyroid cancer (FTC) and follicular thyroid adenoma (FTA) constitutes a long-standing diagnostic problem resulting in equivocal histopathological diagnoses. There is therefore a need for additional molecular markers. To identify molecular differences between FTC and FTA, we analyzed the gene expression microarray data of 52 follicular neoplasms. We also performed a meta-analysis involving 14 studies employing high throughput methods (365 follicular neoplasms analyzed). Based on these two analyses, we selected 18 genes differentially expressed between FTA and FTC. We validated them by quantitative real-time polymerase chain reaction (qRT-PCR) in an independe…

0301 basic medicinePathologyMicroarrayThyroid Glandlaw.inventionlawFollicular phaseGene expressionAdenocarcinoma Follicularfollicular thyroid adenoma; follicular thyroid cancer; gene expression; microarray; meta-analysisSpectroscopyPolymerase chain reactionOligonucleotide Array Sequence Analysisfollicular thyroid cancerGeneral MedicineCANCERComputer Science ApplicationsGene Expression Regulation NeoplasticCARCINOMASFUSION ONCOGENEmicroarrayNEOPLASMSmedicine.medical_specialtyMOLECULAR MARKERSASPIRATIONBiologyCatalysisCLASSIFICATIONArticleInorganic Chemistry03 medical and health sciencesNODULESADENOMASmedicineBiomarkers TumorHumansRNA MessengerThyroid NeoplasmsPhysical and Theoretical ChemistryFollicular thyroid cancerMolecular BiologyGeneGene Expression ProfilingOrganic ChemistryThyroid adenomaACVRL1medicine.diseaseMODELmeta-analysis030104 developmental biologyfollicular thyroid adenomaMutationgene expressionInternational Journal of Molecular Sciences
researchProduct

Performance of Contrast-Enhanced Ultrasound in Thyroid Nodules: Review of Current State and Future Perspectives

2021

Simple Summary Ultrasound has been used as baseline imaging for thyroid nodules for decades; nevertheless, no single feature is sensitive or specific enough to exclude or confirm thyroid malignancy. Therefore, clinical practice and research still focus on less invasive diagnostic patterns to reduce unnecessary fine-needle aspiration biopsies or surgery. The main advantage of CEUS is the ability to assess the sequence and intensity of vascular perfusion and hemodynamics in the thyroid nodule, thus providing real-time characterization of nodule features, and considered a valuable new approach in the determination of benign vs. malignant nodules. In addition, contrast agents used in CEUS can h…

Thyroid nodulesCancer Researchmedicine.medical_specialtycontrast-enhanced ultrasound (CEUS)ReviewMalignancyPapillary thyroid cancermedicinethyroid cancerpapillary thyroid cancerFollicular thyroid cancerThyroid cancerRC254-282business.industrythyroid nodulesfollicular thyroid cancerThyroidNeoplasms. Tumors. Oncology. Including cancer and carcinogensNodule (medicine)medicine.diseasemedicine.anatomical_structureOncologycontrast-enhanced ultrasound (CEUS); follicular thyroid cancer; papillary thyroid cancer; thyroid cancer; thyroid nodulesRadiologymedicine.symptombusinessContrast-enhanced ultrasoundCancers
researchProduct

A two miRNA classifier differentiates follicular thyroid carcinomas from follicular thyroid adenomas.

2015

The inherent diagnostic limitations of thyroid fine needle aspiration (FNA), especially in the "indeterminate" category, can be partially overcome by molecular analyses. We aimed at the identification of miRNAs that could be used to improve the discrimination of indeterminate FNAs. miRNA expression profiling was performed for 17 follicular carcinomas (FTCs) and 8 follicular adenomas (FAs). The microarray results underwent cross-comparison using three additional microarray data sets. Candidate miRNAs were validated by qPCR in an independent set of 32 FTCs and 46 FAs. Sixty-eight differentially expressed miRNAs were identified. Thirteen miRNAs could be confirmed by cross comparison. A two-miR…

Thyroid nodulesMaleMicroarrayThyroid Neoplasms/classificationBiologyBioinformaticsClassifierMicroRNAs/biosynthesisBiochemistryFollicular thyroid cancerThyroid carcinomaAdenocarcinoma Follicular/classificationEndocrinologyAdenocarcinoma FollicularDatabases GeneticmedicineHumansRNA NeoplasmThyroid NeoplasmsFollicular thyroid cancerMolecular Biologymedicine.diagnostic_testMicroarray analysis techniquesThyroidmedicine.diseaseGene Expression Regulation NeoplasticMicroRNAsFine-needle aspirationmedicine.anatomical_structureCancer researchFemaleFollicular thyroid adenomaIndeterminateRNA Neoplasm/biosynthesisMolecular and cellular endocrinology
researchProduct

Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas.

2013

The objective of the study was to identify microRNAs (miRs) characteristic for follicular thyroid carcinoma (FTC) and to define their role in tumorigenesis. A miR-microarray study was conducted to identify miRs differentially expressed between FTCs and their surrounding tissues. Selection was further reinforced by a literature review. Four miRs were selected and confirmed by RT-qPCR: miR-146b, -183, -221 were up-regulated, whereas miR-199b down-regulated in FTCs. The influence of these miRs on cell proliferation, cell cycle, apoptosis and migration was studied in HTori and FTC-133 cells. Functional characterization suggests an impact of miR-183 and miR-146b in FTC development. Overexpressio…

medicine.medical_specialtyApoptosisBiologymedicine.disease_causeBiochemistryThyroid carcinomaEndocrinologyCell MovementInternal medicineCell Line TumorFollicular phasemicroRNAAdenocarcinoma FollicularmedicineHumansThyroid NeoplasmsFollicular thyroid cancerMolecular BiologyCell ProliferationCell growthCell cyclemedicine.diseaseGene Expression Regulation NeoplasticMicroRNAsEndocrinologyApoptosisCancer researchCarcinogenesisMolecular and cellular endocrinology
researchProduct

Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea

2019

Background: Thyroid cancer has become the most common cancer in Korea. Generally, thyroid cancer patients have a good prognosis; however, 15–20% of patients experience recurrence or distant metastasis or are refractory to standard treatment. We assessed the safety of sorafenib and lenvatinib in patients with advanced or metastatic radioactive iodine-refractory differentiated thyroid cancers (DTC) consecutively treated at a tertiary center in South Korea.Methods: We retrospectively reviewed the charts of all consecutive patients with DTC treated during ≥6 months with lenvatinib (February 2016–April 2018) and sorafenib (January 2014–April 2018) at Gangnam Severance Hospital. Patients were tre…

safety0301 basic medicineSorafenibmedicine.medical_specialtyEndocrinology Diabetes and Metabolismdifferentiated thyroid cancerrefractory thyroid cancer030209 endocrinology & metabolismlenvatiniblcsh:Diseases of the endocrine glands. Clinical endocrinologyGastroenterologyPapillary thyroid cancer03 medical and health scienceschemistry.chemical_compoundEndocrinology0302 clinical medicineInternal medicinetyrosine kinase inhibitorsmedicineAdverse effectFollicular thyroid cancerThyroid cancerOriginal Researchlcsh:RC648-665business.industryStandard treatmentCancermedicine.disease030104 developmental biologychemistryadverse effectschart reviewsorafenibbusinessLenvatinibmedicine.drugFrontiers in Endocrinology
researchProduct